BioComo Incorporation
Corporate Profile
Biocomo Incorporation is engaged in development of innovative biological vaccines.
Its missions are to create infectious vaccines that the human being have not overcome such as RSV and Ebola and to create most efficient, cost effective and safe cancer vaccines utilizing its high immunogenicity characteristics.
Technology
BC-PIV is our core platform technology which was named after our corporate name, BioComo and our leading vaccine carrier is derived from the recombinant human parainfluenza virus 2 (hPIV2) vectors.
Pipeline
Information
- 2021-3-12
- New patent application for Coronavirus (SARS-CoV-2) Vaccine using BC-PIV vector has been filed(pdf)
- 2021-2-23
- BioComo and Mie University announce initiation of joint development of vaccines for SARS-CoV-2 variants using BC-PIV vector(pdf)
- 2020-3
- Notice of embarking on SARS-CoV-2 vaccine development (pdf)
- 2020-2
- Scrip features BC-PIV based new anti-tumor TNFRSF Signal Activator entitled “Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology”
https://scrip.pharmaintelligence.informa.com/SC141702/Japans-BioComo-Pursues-Novel-Ligand-Approach-To-ImmunoOncology - 2019-10
- New Immuno-oncology treatment, anti-tumor TNFRSF Signal Activator was introduced at Japan Healthcare Venture Summit 2019 (Bio Japan) in Yokohama
- 2019-8
- BioComo’s Principal Scientist, Junpei Ohtsuka, Ph.D. published a scientific paper entitled “A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2 vector (2019) 9:12901” as a lead author at Scientific Reports
- 2019-6
- New Immuno-oncology treatment, anti-tumor TNFRSF Signal Activator was introduced at BIO2019 (Philadelphia)
- 2018-10
- New Immuno-oncology treatment enhanced by NK/Tcell activity was introduced at Japan Healthcare Venture Summit 2018 (Bio Japa) in Yokohama (summary is linked here)
- 2018-05
- Recently developed new pipeline products using BC-PIV platform in infectious vaccines (RSV, Zika and Ebola) and in cancer immunotherapy activating T cells will be presented at JETRO booth of BIO 2018 in Boston.
- 2017-10
- Biocomo will present a poster, titled as “A structure based vaccine by a non-transmissible human parainfluenza virus vector” at 2017 International Society for Vaccines (ISV) Annual Congress at the Institute Pasteur in Paris on October 5th ? 7th
- 2017-07
- The US patent, titled as “Vaccine Prepared Utilizing Human Parainfluenza Virus Type 2 Vector” was granted on June 4, 2017
- 2017-06
- The European Patent titled as “method for producing virus vector gene transfer” was granted on June 14, 2017.
- 2016-07
- The US patent, titled as “Vaccine Prepared Utilizing Human Parainfluenza Virus Type 2 Vector” was granted on June 4, 2017
- 2016-01
- Biocomo participated in Biotech Showcase in San Francisco
- 2015-11
- BioComo exhibited at Bio Europe.
- 2015-10
- Bioomo exhibited at Bio Japan.